Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis

Zeng,Chensi; Li,Xingxin; Li,Anmao; Yi,Bei; Peng,Xi; Huang,Xi; Chen,Jianbin

doi:10.3892/or.2018.6544

Knockdown of NUPR1 inhibits the growth of U266 and RPMI8226 multiple myeloma cell lines via activating PTEN and caspase activation‑dependent apoptosis

Authors:
- Chensi Zeng
- Xingxin Li
- Anmao Li
- Bei Yi
- Xi Peng
- Xi Huang
- Jianbin Chen
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China, Department of Hematology, Hechuan Hospital of The First Affiliated Hospital of Chongqing Medical University, Chongqing 401520, P.R. China
Published online on: July 4, 2018 https://doi.org/10.3892/or.2018.6544
Pages: 1487-1494

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nuclear protein‑1 (NUPR1) is a stress response factor that is important in the development of several human malignant tumor cells. However, the role of NUPR1 in multiple myeloma (MM) remains to be fully elucidated. In the present study, it was found that the mRNA levels of NUPR1 were significantly higher in specimens from patients with MM and MM cell lines (U266 and RPMI8226) than in cells of normal human bone marrow. The present study was undertaken to investigate the function of NUPR1 in the growth and apoptosis of MM cell lines. A lentivirus‑mediated short hairpin RNA was used to specifically inhibit the mRNA and protein expression of NUPR1 in the U266 and RPMI8226 MM cell lines. Flow cytometry and Cell Counting Kit‑8 assays were applied to examine the apoptosis and proliferation of U266 and RPMI8226 cell lines. The results revealed the inhibitory effect of NUPR1 silencing on the proliferation of U266 and RPMI8226 cells through inducing apoptosis, and arrest of cell cycle at the G0/G1 phase. Furthermore, NUPR1 silencing caused activation of caspase‑3, ‑8 and ‑9 and influenced specific gene expression, including an increase of phosphatase and tensin homolog (PTEN) and decrease of B‑cell lymphoma 2 and proliferating cell nuclear antigen. These findings showed that NUPR1 may be involved in the proliferation and apoptosis of MM cells by adjusting caspase proteins and PTEN, suggesting that NUPR1 may be a novel therapeutic target for MM.

View Figures

View References

1	Mohamed AN, Bentley G, Bonnett ML, Zonder J and Al-Katib A: Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. Am J Hematol. 82:1080–1087. 2007. View Article : Google Scholar : PubMed/NCBI
2	Dupéré-Richer D and Licht JD: Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma. Curr Opin Hematol. 24:336–344. 2017. View Article : Google Scholar : PubMed/NCBI
3	Manier S, Salem KZ, Park J, Landau DA, Getz G and Ghobrial IM: Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 14:100–113. 2017. View Article : Google Scholar : PubMed/NCBI
4	Mallo GV, Fiedler F, Calvo EL, Ortiz EM, Vasseur S, Keim V, Morisset J and Lovanna JL: Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development, and regeneration, and which promotes cellular growth. J Biol Chem. 272:32360–32369. 1997. View Article : Google Scholar : PubMed/NCBI
5	Cano CE, Hamidi T, Sandi MJ and Iovanna JL: Nupr1: The Swiss-knife of cancer. J Cell Physiol. 226:1439–1443. 2011. View Article : Google Scholar : PubMed/NCBI
6	Sandi MJ, Hamidi T, Malicet C, Cano C, Loncle C, Pierres A, Dagorn JC and Lovanna JL: p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis. J Cell Physiol. 226:3442–3451. 2011. View Article : Google Scholar : PubMed/NCBI
7	Emma MR, Iovanna JL, Bachvarov D, Puleio R, Loria GR, Auqello G, Candido S, Libra M, Gulino A, Cancila V, et al: NUPR1, a new target in liver cancer: Implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death Dis. 7:e22692016. View Article : Google Scholar : PubMed/NCBI
8	Veerla S, Panagopoulos I, Jin Y, Lindgren D and Höglund M: Promoter analysis of epigenetically controlled genes in bladder cancer. Genes Chromosomes Cancer. 47:368–378. 2008. View Article : Google Scholar : PubMed/NCBI
9	Ito Y, Yoshida H, Motoo Y, Lovanna JL, Nakamura Y, Kakudo K, Uruno T, Takamura Y, Miya A, Noquchi S, et al: Expression of p8 protein in breast carcinoma; an inverse relationship with apoptosis. Anticancer Res. 25:833–837. 2005.PubMed/NCBI
10	Di Martino MT, Guzzi PH, Caracciolo D, Aqnelli L, Neri A, Walker BA, Morqan GJ, Cannataro M, Tassone P and Taqliaferri P: Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget. 6:19132–19147. 2015. View Article : Google Scholar : PubMed/NCBI
11	Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, et al: Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
12	Scherr M and Eder M: Gene transfer into hematopoietic stem cells using lentiviral vectors. Curr Gene Ther. 2:45–55. 2002. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Guo X, Wang W, Hu J, Feng K, Pan Y, Zhang L and Feng L: Lentivirus-mediated RNAi knockdown of NUPR1 inhibits human nonsmall cell lung cancer growth in vitro and in vivo. Anat Rec. 295:2114–2121. 2012. View Article : Google Scholar
15	Pedrola N, Devis L, Llauradó M, Campoy I, Martinez-Garcia E, Garcia M, Muinelo-Romay L, Alonso-Alconada L, Abal M, Alameda F, et al: Nidogen 1 and nuclear protein 1: Novel targets of ETV5 transcription factor involved in endometrial cancer invasion. Clin Exp Metastasis. 32:467–478. 2015. View Article : Google Scholar : PubMed/NCBI
16	Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD and Fodstad O: Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int J Mol Med. 18:981–986. 2006.PubMed/NCBI
17	Kong DK, Georgescu SP, Cano C, Aronovitz MJ, Lovanna JL, Patten RD, Kyriakis JM and Goruppi S: Deficiency of the transcriptional regulator p8 results in increased autophagy and apoptosis, and causes impaired heart function. Mol Biol Cell. 21:1335–1349. 2010. View Article : Google Scholar : PubMed/NCBI
18	Goruppi S and Iovanna JL: Stress-inducible protein p8 is involved in several physiological and pathological processes. J Biol Chem. 285:1577–1581. 2010. View Article : Google Scholar : PubMed/NCBI
19	Li J, Ren S, Liu Y, Lian Z, Dong B, Yao Y and Xu Y: Knockdown of NUPR1 inhibits the proliferation of glioblastoma cells via ERK1/2, p38 MAPK and caspase-3. J Neurooncol. 132:15–26. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lorente M, Carracedo A, Torres S, Natali F, Eqia A, Hernández-Tiedra S, Salazar M, Blázquez C, Guzman M and Velasco G: Amphiregulin is a factor for resistance of glioma cells to cannabinoid-induced apoptosis. Glia. 57:1374–1385. 2009. View Article : Google Scholar : PubMed/NCBI
21	Su SB, Motoo Y, Iovanna JL, Berthézène P, Xie MJ, Mouri H, Ohtsubo K, Matsubara F and Sawabu N: Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. Clin Cancer Res. 7:1320–1324. 2001.PubMed/NCBI
22	Malicet C, Giroux V, Vasseur S, Dagorn JC, Neira JL and Iovanna JL: Regulation of apoptosis by the p8/prothymosin alpha complex. Proc Natl Acad Sci USA. 103:2671–2676. 2006. View Article : Google Scholar : PubMed/NCBI
23	Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
24	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
25	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
26	Reed JC and Pellecchia M: Apoptosis-based therapies for hematologic malignancies. Blood. 106:408–418. 2005. View Article : Google Scholar : PubMed/NCBI
27	Mahler M, Miyachi K, Peebles C and Fritzler MJ: The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmun Rev. 11:771–775. 2012. View Article : Google Scholar : PubMed/NCBI
28	Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, et al: PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA. 106:19479–19484. 2009. View Article : Google Scholar : PubMed/NCBI
29	Song L, Liu S, Zhang L, Yao H, Gao F, Xu D and Li Q: MiR-21 modulates radiosensitivity of cervical cancer through inhibiting autophagy via the PTEN/Akt/HIF-1alpha feedback loop and the Akt-mTOR signaling pathway. Tumour Biol. 37:12161–12168. 2016. View Article : Google Scholar : PubMed/NCBI
30	Wang DD, Yang SJ, Chen X, Shen HY, Luo LJ, Zhang XH, Zhong SL, Zhao JH and Tang JH: miR-222 induces Adriamycin resistance in breast cancer through PTEN/Akt/p27^kip1 pathway. Tumour Biol. 37:15315–15324. 2016. View Article : Google Scholar : PubMed/NCBI
31	Zhu DY, Li XN, Qi Y, Liu DL, Yang Y, Zhao J, Zhang CY, Wu K and Zhao S: MiR-454 promotes the progression of human non-small cell lung cancer and directly targets PTEN. Biomed Pharmacother. 81:79–85. 2016. View Article : Google Scholar : PubMed/NCBI
32	Xiaozhou L, Xing Z, Haidong X, Zhiwei H, Xin S and Sujia W: SLC34A2 regulates the proliferation, migration, and invasion of human osteosarcoma cells through PTEN/PI3K/AKT signaling. DNA Cell Biol. 36:775–780. 2017.PubMed/NCBI
33	Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: Rationale and importance to inhibiting these pathways in human health. Oncotarget. 2:135–164. 2011. View Article : Google Scholar : PubMed/NCBI
34	Yang F, Shi L, Liang T, Ji L, Zhang G, Shen Y, Zhu F and Xu L: Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma. Biochem Biophys Res Commun. 485:54–61. 2017. View Article : Google Scholar : PubMed/NCBI